Demographic and Baseline Characteristics of 414 Participants Enrolled and Randomized in Both Seasons of 2-Year Randomized Trial of Quadrivalent Non–Egg-based vs Egg-Based Licensed Influenza Vaccines According to Vaccines Received in Each Study Season
| Characteristic . | IIV/IIV . | ccIIV/ccIIV . | ccIIV/RIV . | RIV/ccIIV . | RIV/RIV . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 60 . | n = 101 . | n = 106 . | n = 73 . | n = 74 . | ||||||
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| Demographic | ||||||||||
| ȃAge, mean, (SD), years | 46 | (11) | 46 | (11) | 46 | (11) | 47 | (11) | 46 | (11) |
| ȃAge group, years | ||||||||||
| ȃȃ18–44 | 22 | (37) | 42 | (42) | 44 | (42) | 28 | (38) | 30 | (41) |
| ȃȃ45–64 | 38 | (63) | 59 | (58) | 62 | (58) | 45 | (62) | 44 | (59) |
| ȃFemale | 54 | (90) | 83 | (82) | 87 | (82) | 58 | (79) | 56 | (78) |
| ȃWhite | 47 | (78) | 83 | (82) | 88 | (83) | 56 | (77) | 54 | (73) |
| ȃHispanic | 10 | (17) | 10 | (10) | 18 | (17) | 11 | (15) | 10 | (22) |
| ȃSite | ||||||||||
| ȃȃBaylor Scott & White Health | 41 | (68) | 55 | (54) | 61 | (58) | 57 | (78) | 56 | (76) |
| ȃȃKaiser Permanente Northwest | 19 | (32) | 46 | (46) | 45 | (42) | 16 | (22) | 18 | (24) |
| Baseline | ||||||||||
| ȃBody mass index, mean (SD) | 30 | (7) | 29 | (7) | 30 | (7) | 29 | (6) | 30 | (7) |
| ȃSubjective health status, mean (SD)a | 4 | (1) | 4 | (1) | 4 | (1) | 4 | (1) | 4 | (1) |
| ȃDiagnosed or treated for chronic medical condition during the past 12 months | 11 | (18) | 8 | (8) | 13 | (12) | 7 | (10) | 8 | (11) |
| ȃImmunosuppressive condition | 1 | (2) | 0 | (0) | 2 | (2) | 2 | (3) | 1 | (1) |
| ȃSmokerb | 4 | (6) | 5 | (5) | 3 | (3) | 2 | (3) | 6 | (8) |
| ȃPregnantc | 2 | (11) | 0 | (0) | 1 | (3) | 0 | (0) | 1 | (5) |
| ȃPrior influenza vaccination receiptd | ||||||||||
| ȃTotal vaccines received during the preceding 6 seasons, mean (SD)d | 6 | (1) | 6 | (1) | 6 | (1) | 6 | (1) | 6 | (1) |
| Characteristic . | IIV/IIV . | ccIIV/ccIIV . | ccIIV/RIV . | RIV/ccIIV . | RIV/RIV . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 60 . | n = 101 . | n = 106 . | n = 73 . | n = 74 . | ||||||
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| Demographic | ||||||||||
| ȃAge, mean, (SD), years | 46 | (11) | 46 | (11) | 46 | (11) | 47 | (11) | 46 | (11) |
| ȃAge group, years | ||||||||||
| ȃȃ18–44 | 22 | (37) | 42 | (42) | 44 | (42) | 28 | (38) | 30 | (41) |
| ȃȃ45–64 | 38 | (63) | 59 | (58) | 62 | (58) | 45 | (62) | 44 | (59) |
| ȃFemale | 54 | (90) | 83 | (82) | 87 | (82) | 58 | (79) | 56 | (78) |
| ȃWhite | 47 | (78) | 83 | (82) | 88 | (83) | 56 | (77) | 54 | (73) |
| ȃHispanic | 10 | (17) | 10 | (10) | 18 | (17) | 11 | (15) | 10 | (22) |
| ȃSite | ||||||||||
| ȃȃBaylor Scott & White Health | 41 | (68) | 55 | (54) | 61 | (58) | 57 | (78) | 56 | (76) |
| ȃȃKaiser Permanente Northwest | 19 | (32) | 46 | (46) | 45 | (42) | 16 | (22) | 18 | (24) |
| Baseline | ||||||||||
| ȃBody mass index, mean (SD) | 30 | (7) | 29 | (7) | 30 | (7) | 29 | (6) | 30 | (7) |
| ȃSubjective health status, mean (SD)a | 4 | (1) | 4 | (1) | 4 | (1) | 4 | (1) | 4 | (1) |
| ȃDiagnosed or treated for chronic medical condition during the past 12 months | 11 | (18) | 8 | (8) | 13 | (12) | 7 | (10) | 8 | (11) |
| ȃImmunosuppressive condition | 1 | (2) | 0 | (0) | 2 | (2) | 2 | (3) | 1 | (1) |
| ȃSmokerb | 4 | (6) | 5 | (5) | 3 | (3) | 2 | (3) | 6 | (8) |
| ȃPregnantc | 2 | (11) | 0 | (0) | 1 | (3) | 0 | (0) | 1 | (5) |
| ȃPrior influenza vaccination receiptd | ||||||||||
| ȃTotal vaccines received during the preceding 6 seasons, mean (SD)d | 6 | (1) | 6 | (1) | 6 | (1) | 6 | (1) | 6 | (1) |
Abbreviations: ccIIV, cell culture–based inactivated influenza vaccine (Flucelvax Quadrivalent); IIV, quadrivalent inactivated influenza vaccine (Fluzone Quadrivalent); RIV, recombinant-hemagglutinin IIV (Flublok Quadrivalent); SD, standard deviation.
Original answer choice converted to numeric scale where 5 = excellent and 1 = poor. Responses were missing for 5 participants.
Participant was considered a smoker if participant answered currently smokes every day or some days. Responses were missing for 5 participants.
Among 131 female participants with nonmissing responses.
Based on report of vaccination by participant interview or electronic medical record extraction.
Demographic and Baseline Characteristics of 414 Participants Enrolled and Randomized in Both Seasons of 2-Year Randomized Trial of Quadrivalent Non–Egg-based vs Egg-Based Licensed Influenza Vaccines According to Vaccines Received in Each Study Season
| Characteristic . | IIV/IIV . | ccIIV/ccIIV . | ccIIV/RIV . | RIV/ccIIV . | RIV/RIV . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 60 . | n = 101 . | n = 106 . | n = 73 . | n = 74 . | ||||||
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| Demographic | ||||||||||
| ȃAge, mean, (SD), years | 46 | (11) | 46 | (11) | 46 | (11) | 47 | (11) | 46 | (11) |
| ȃAge group, years | ||||||||||
| ȃȃ18–44 | 22 | (37) | 42 | (42) | 44 | (42) | 28 | (38) | 30 | (41) |
| ȃȃ45–64 | 38 | (63) | 59 | (58) | 62 | (58) | 45 | (62) | 44 | (59) |
| ȃFemale | 54 | (90) | 83 | (82) | 87 | (82) | 58 | (79) | 56 | (78) |
| ȃWhite | 47 | (78) | 83 | (82) | 88 | (83) | 56 | (77) | 54 | (73) |
| ȃHispanic | 10 | (17) | 10 | (10) | 18 | (17) | 11 | (15) | 10 | (22) |
| ȃSite | ||||||||||
| ȃȃBaylor Scott & White Health | 41 | (68) | 55 | (54) | 61 | (58) | 57 | (78) | 56 | (76) |
| ȃȃKaiser Permanente Northwest | 19 | (32) | 46 | (46) | 45 | (42) | 16 | (22) | 18 | (24) |
| Baseline | ||||||||||
| ȃBody mass index, mean (SD) | 30 | (7) | 29 | (7) | 30 | (7) | 29 | (6) | 30 | (7) |
| ȃSubjective health status, mean (SD)a | 4 | (1) | 4 | (1) | 4 | (1) | 4 | (1) | 4 | (1) |
| ȃDiagnosed or treated for chronic medical condition during the past 12 months | 11 | (18) | 8 | (8) | 13 | (12) | 7 | (10) | 8 | (11) |
| ȃImmunosuppressive condition | 1 | (2) | 0 | (0) | 2 | (2) | 2 | (3) | 1 | (1) |
| ȃSmokerb | 4 | (6) | 5 | (5) | 3 | (3) | 2 | (3) | 6 | (8) |
| ȃPregnantc | 2 | (11) | 0 | (0) | 1 | (3) | 0 | (0) | 1 | (5) |
| ȃPrior influenza vaccination receiptd | ||||||||||
| ȃTotal vaccines received during the preceding 6 seasons, mean (SD)d | 6 | (1) | 6 | (1) | 6 | (1) | 6 | (1) | 6 | (1) |
| Characteristic . | IIV/IIV . | ccIIV/ccIIV . | ccIIV/RIV . | RIV/ccIIV . | RIV/RIV . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 60 . | n = 101 . | n = 106 . | n = 73 . | n = 74 . | ||||||
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| Demographic | ||||||||||
| ȃAge, mean, (SD), years | 46 | (11) | 46 | (11) | 46 | (11) | 47 | (11) | 46 | (11) |
| ȃAge group, years | ||||||||||
| ȃȃ18–44 | 22 | (37) | 42 | (42) | 44 | (42) | 28 | (38) | 30 | (41) |
| ȃȃ45–64 | 38 | (63) | 59 | (58) | 62 | (58) | 45 | (62) | 44 | (59) |
| ȃFemale | 54 | (90) | 83 | (82) | 87 | (82) | 58 | (79) | 56 | (78) |
| ȃWhite | 47 | (78) | 83 | (82) | 88 | (83) | 56 | (77) | 54 | (73) |
| ȃHispanic | 10 | (17) | 10 | (10) | 18 | (17) | 11 | (15) | 10 | (22) |
| ȃSite | ||||||||||
| ȃȃBaylor Scott & White Health | 41 | (68) | 55 | (54) | 61 | (58) | 57 | (78) | 56 | (76) |
| ȃȃKaiser Permanente Northwest | 19 | (32) | 46 | (46) | 45 | (42) | 16 | (22) | 18 | (24) |
| Baseline | ||||||||||
| ȃBody mass index, mean (SD) | 30 | (7) | 29 | (7) | 30 | (7) | 29 | (6) | 30 | (7) |
| ȃSubjective health status, mean (SD)a | 4 | (1) | 4 | (1) | 4 | (1) | 4 | (1) | 4 | (1) |
| ȃDiagnosed or treated for chronic medical condition during the past 12 months | 11 | (18) | 8 | (8) | 13 | (12) | 7 | (10) | 8 | (11) |
| ȃImmunosuppressive condition | 1 | (2) | 0 | (0) | 2 | (2) | 2 | (3) | 1 | (1) |
| ȃSmokerb | 4 | (6) | 5 | (5) | 3 | (3) | 2 | (3) | 6 | (8) |
| ȃPregnantc | 2 | (11) | 0 | (0) | 1 | (3) | 0 | (0) | 1 | (5) |
| ȃPrior influenza vaccination receiptd | ||||||||||
| ȃTotal vaccines received during the preceding 6 seasons, mean (SD)d | 6 | (1) | 6 | (1) | 6 | (1) | 6 | (1) | 6 | (1) |
Abbreviations: ccIIV, cell culture–based inactivated influenza vaccine (Flucelvax Quadrivalent); IIV, quadrivalent inactivated influenza vaccine (Fluzone Quadrivalent); RIV, recombinant-hemagglutinin IIV (Flublok Quadrivalent); SD, standard deviation.
Original answer choice converted to numeric scale where 5 = excellent and 1 = poor. Responses were missing for 5 participants.
Participant was considered a smoker if participant answered currently smokes every day or some days. Responses were missing for 5 participants.
Among 131 female participants with nonmissing responses.
Based on report of vaccination by participant interview or electronic medical record extraction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
